"ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM)" by Andrew Lassman

Article

ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM)

Neuro-oncology (2017)

Andrew Lassman, Columbia University
Cara Dimino
Mahesh Mansukhani, Columbia University
Vundavalli Murty, Columbia University
Peter J Ansell
Earle Bain
Kyle D Holen, University of Wisconsin-Madison
Lisa A Roberts-Rapp
James Lee
Walter Curran, Emory University
Minesh P Mehta, University of Maryland, Baltimore
Peter Canoll, Columbia University

Link

Disciplines

Publication Date

November 6, 2017

DOI

10.1093/neuonc/nox168.055

Citation Information

Andrew Lassman, Cara Dimino, Mahesh Mansukhani, Vundavalli Murty, et al.. "ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM)" Neuro-oncology Vol. 19 (2017)
Available at: http://works.bepress.com/minesh-mehta/8/